Please login to the form below

Not currently logged in
Email:
Password:

John LaMattina joins Frequency Therapeutics in advisory role

The ex-Pfizer R&D head will sit on its Scientific Advisory Board

John LaMattinaFrequency Therapeutics has appointed John LaMattina as its senior advisor to the CEO in a role that will see him focus on assisting its development of a treatment for hearing loss, serving on the firm’s Scientific Advisory Board.

LaMattina was previously president of Pfizer’s Global Research and Development department and senior vice president and spent 30 years at the pharma company.

He said: “It is my pleasure to join Frequency Therapeutics as it begins clinical development of a treatment for hearing loss.

“The team has made remarkably rapid progress, and Frequency’s Progenitor Cell Activation platform presents an exceptional opportunity to develop a wide range of new-disease modifying therapies for hearing and other areas throughout the body.”

Alongside his new role LaMattina will continue to serve as an independent non-executive director at PureTech Health.

David Lucchino, president, co-founder and CEO of Frequences Therapeutics, said: “As a highly-regarded industry veteran, John brings us a wealth of knowledge and expertise.

"John has already begun to help us accelerate the development of our pipeline of product candidates for hearing restoration.”

4th April 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics